Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy.
Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, Niedzwecki B, Liu H, Kokolus KM, Eng JW, Messmer MN, Attwood K, Abrams SI, Hylander BL, Repasky EA. Bucsek MJ, et al. Among authors: attwood k. Cancer Res. 2017 Oct 15;77(20):5639-5651. doi: 10.1158/0008-5472.CAN-17-0546. Epub 2017 Aug 17. Cancer Res. 2017. PMID: 28819022 Free PMC article.
Predictive and Prognostic Implications of Circulating CX3CR1+ CD8+ T Cells in Non-Small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy.
Abdelfatah E, Long MD, Kajihara R, Oba T, Yamauchi T, Chen H, Sarkar J, Attwood K, Matsuzaki J, Segal BH, Dy GK, Ito F. Abdelfatah E, et al. Among authors: attwood k. Cancer Res Commun. 2023 Mar 30;3(3):510-520. doi: 10.1158/2767-9764.CRC-22-0383. eCollection 2023 Mar. Cancer Res Commun. 2023. PMID: 37009132 Free PMC article.
Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx.
Gandhi S, Opyrchal M, Grimm MJ, Slomba RT, Kokolus KM, Witkiewicz A, Attwood K, Groman A, Williams L, Tarquini ML, Wallace PK, Soh KT, Minderman H, Maguire O, O'Connor TL, Early AP, Levine EG, Kalinski P. Gandhi S, et al. Among authors: attwood k. J Immunother Cancer. 2023 Nov;11(11):e007381. doi: 10.1136/jitc-2023-007381. J Immunother Cancer. 2023. PMID: 37963636 Free PMC article.
Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Gandhi S, Slomba RT, Janes C, Fitzpatrick V, Miller J, Attwood K, Ioannou G, Ozbey S, De Souza I, Roudko V, Kumar P, Kalathil S, Kokolus KM, Wang J, Cortes Gomez E, Takabe K, Edge S, Young J, Cappuccino H, Opyrchal M, O'Connor T, Levine EG, Gnjatic S, Kalinski P. Gandhi S, et al. Among authors: attwood k. J Immunother Cancer. 2024 Nov 14;12(11):e010058. doi: 10.1136/jitc-2024-010058. J Immunother Cancer. 2024. PMID: 39542655 Free PMC article. Clinical Trial.
Prognostic immune markers in esophageal cancer patients managed with trimodal therapy.
Farrugia MK, Repasky EA, Chen M, Attwood K, Catalfamo K, Rosenheck H, Yao S, Mattson DM, Mukherjee S, Kukar M, Witkiewicz AK, Singh AK. Farrugia MK, et al. Among authors: attwood k. Cancer Immunol Immunother. 2025 Jan 3;74(2):57. doi: 10.1007/s00262-024-03891-3. Cancer Immunol Immunother. 2025. PMID: 39751903 Free PMC article.
300 results